HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Crandon v. Maybelline

This article was originally published in The Rose Sheet

Executive Summary

Crandon v. Maybelline: Maybelline stockholder Crandon Capital Partners filed class action suit seeking an injunction to block the merger between Maybelline and Paris-based L'Oreal S.A., according to a Dec. 11 complaint. Crandon is charging the cosmetic company with "breach of...fiduciary duties owed to Maybelline's stockholders to take all necessary steps to ensure that the stockholders will receive the maximum value realizable for their shares." Crandon alleged that Maybelline did not "retain an independent investment banker to advise them as to Maybelline's value as an acquisition candidate" and instead relied on advice from Wasserstein, Perella -- Maybelline's largest shareholder -- which "has its own personal reasons to agree to the [merger] without necessarily achieving the best terms for Maybelline's public shareholders." Filed in Chancery Court in Delaware, the complaint requires defendants to "place [Maybelline] up for auction and/or conduct a market-check prior to" selling the company. The suit was filed the day after the announcement that L'Oreal would acquire Maybelline ("The Rose Sheet" Dec. 18, p. 1)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel